• Founded on over two decades of research, the Company was formed in 2014 and listed on the UK stock market.
  • From the outset, we constructed a library of bacteria isolated from healthy human samples, which now stands at more than 8,000 strains.
  • We have built a drug discovery platform, known as MicroRx, which has shown the ability to rapidly identify bacteria from our library that have therapeutically relevant effects.
  • To date, the Company has initiated 13 live biotherapeutic programmes across a broad range of diseases.
  • The Company has received FDA Orphan Designation for its programmes in paediatric Crohn’s disease and paediatric Ulcerative Colitis.
  • We have developed humanised preclinical models, which have allowed us to test our products in more disease-relevant settings and improve their translational potential.
  • The Company commenced a clinical study of Blautix in patients with IBS in 2015. This trial was completed in 2017 and successfully reached its primary objective.
  • We have established a proprietary microbiome profiling platform, MicroDx, to analyse the microbiome and aid the diagnosis and treatment of patients.
  • We have completed the first phase of our MicroDx clinical development programme, demonstrating significant differences between the microbiome of IBS patients and healthy individuals, independent of traditional IBS sub-types
  • The Company was granted GMP certification for its ~1,500 m² development and manufacturing facility.
  • We have completed a Phase Ib study of Thetanix in paediatric Crohn's disease, demonstrating safety and tolerability.
  • The Company has initiated a large, multi-centre Phase II study of Blautix in patients with IBS-C and IBS-D, which will enrol up to 500 patients.
  • We have entered a clinical collaboration with Merck & Co. to evaluate our lead immuno-oncology candidate, MRx0518, in combination with the checkpoint inhibitor Keytruda®. As part of this collaboration we have initiated a Phase I/II trial in solid tumours. This trial is being conducted at the University of Texas MD Anderson Cancer Center, with which we have a long-term strategic alliance.


BACK TO TOP